Vaccines have made a significant difference in the risk of severe outcomes associated with COVID-19. Over the last 2.5 years, new variants have occurred that have led to changes in transmissibility and outcomes compared to the original SARS-CoV-2 virus. The omicron variant has significant mutations that are associated with an increase in transmissibility and higher risk of immune escape from current vaccines. The recently approved bivalent mRNA vaccines offer a different strategy to address the omicron variant. In this webinar, experts will review the key clinical considerations for this new booster so healthcare professionals can address:
- Why the bivalent booster was introduced
- How it compares to current boosters in terms of immune response
- The safety of this new vaccine option
- Common patient questions regarding the bivalent booster option
This program has received funding from Moderna.